Sickle Cell Disease Treatment Global Market Report 2025

Description

Sickle cell disease (SCD), also referred to as sickle cell anemia, is a genetic disorder that impacts hemoglobin, a protein found in red blood cells. Individuals with sickle cell disease produce defective hemoglobin, known as hemoglobin S (HbS), due to a mutation in the hemoglobin gene. Treatment for sickle cell disease aims to alleviate blockages, improve blood flow, and repair damaged tissues.

The primary modalities for treating sickle cell disease include blood transfusion, pharmacotherapy, and bone marrow transplant. A blood transfusion involves the transfer of blood or blood products from a donor to a recipient. Sickle cell disease encompasses various types, such as sickle cell anemia, hemoglobin sickle C disease (HbSC), and others, with treatment administered through oral and parenteral routes. End users of these treatments include hospitals, specialty clinics, and other healthcare facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The sickle cell disease treatment market research report is one of a series of new reports from The Business Research Company that provides sickle cell disease treatment market statistics, including sickle cell disease treatment industry global market size, regional shares, competitors with a sickle cell disease treatment market share, detailed sickle cell disease treatment market segments, market trends and opportunities and any further data you may need to thrive in the sickle cell disease treatment industry. This sickle cell disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The sickle cell disease treatment market size has grown rapidly in recent years. It will grow from $2.95 billion in 2024 to $3.51 billion in 2025 at a compound annual growth rate (CAGR) of 18.7%. The growth in the historic period can be attributed to disease understanding, blood transfusions, pain management, hydroxyurea therapy.

The sickle cell disease treatment market size is expected to see rapid growth in the next few years. It will grow to $6.72 billion in 2029 at a compound annual growth rate (CAGR) of 17.7%. The growth in the forecast period can be attributed to gene editing and gene therapy, new drug development, telemedicine and remote monitoring, global health initiatives. Major trends in the forecast period include curative therapies, pain management alternatives, global collaborations, patient advocacy and engagement.

The forecast of 17.7% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for the U.S. by restricting access to gene-editing components and hydroxyurea formulations imported from the UK and France, potentially compromising curative therapy development and increasing hematology department burdens. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing need for blood transfusions is expected to propel the expansion of the sickle cell disease treatment market in the foreseeable future. Blood transfusion is a medical procedure involving the transfer of blood or blood products from a donor to a recipient. It plays a crucial role in the treatment of sickle cell disease (SCD) patients by enhancing the blood's oxygen-carrying capacity and reducing the complications associated with vaso-occlusion. For example, in December 2022, gov.UK reported that the UK witnessed an increase in blood donations in 2021, with 1.7 million donations made across the country. Moreover, in January 2022, according to Mid-Atlantic Long-Term Care, the United States requires approximately 29,000 units of red blood cells, 5,000 units of platelets, and 6,500 units of plasma daily. Therefore, the growing demand for blood transfusions is a driving force behind the growth of the sickle cell disease treatment market.

The increasing number of blood and bone marrow transplants is expected to drive the growth of the sickle cell disease treatment market in the coming years. A blood and bone marrow transplant involves replacing unhealthy blood-forming cells with healthy ones to treat conditions like sickle cell disease. This procedure can involve infusing healthy bone marrow cells either from the patient's own body (autologous transplant) or from a donor (allogeneic transplant). For example, in June 2024, the National Transplant Organization (ONT) reported that Spain added 23,686 donors to its Bone Marrow Donor Registry in 2023, an 8% increase from 2022. The country also achieved a record 3,717 hematopoietic stem cell transplants, translating to 77.4 transplants per million population. As a result, the rising prevalence of blood and bone marrow transplants is expected to significantly boost the sickle cell disease treatment market.

Leading companies in the sickle cell disease (SCD) treatment market are focusing on developing new oral suspension drugs to improve patient compliance, enhance drug efficacy, and provide more convenient treatment options, particularly for pediatric and elderly patients. Oral suspension drugs are liquid medications with solid particles suspended in a liquid, designed to make it easier for patients to swallow, especially children or those who have difficulty with pills. For example, in March 2024, Akums Drugs and Pharmaceuticals Ltd., an India-based pharmaceutical manufacturing company, launched a room temperature-stable oral suspension of Hydroxyurea. This affordable SCD treatment is designed to increase accessibility in India, priced at less than 1% of imported alternatives. It offers precise dosing with oral syringes, providing a solution for patients of all ages without the need for cold storage.

In October 2022, Pfizer Inc., a pharmaceutical corporation headquartered in the United States, acquired Global Blood Therapeutics Inc. for $5.4 billion. This acquisition provides Pfizer with access to a premier sickle cell disease portfolio and pipeline, addressing the critical needs of an underserved patient population. Global Blood Therapeutics Inc. is a biopharmaceutical company based in the United States, specializing in the development and commercialization of therapies for individuals with sickle cell disease (SCD).

Major companies operating in the sickle cell disease treatment market are Sun Pharmaceutical Industries Ltd., Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Silver Lake Research Corporation0.45, Global Blood Therapeutics Inc., Acceleron Pharma Inc., Sangamo Therapeutics Inc., Medunik USA Inc., Zydus Cadila Healthcare Ltd., Graphite Bio Inc., Addmedica, Emmaus Medical Inc., Bluebird bio Inc., CRISPR Therapeutics AG, GlycoMimetics Inc., Arena Pharmaceuticals Inc., Mast Therapeutics Inc.

North America was the largest region in the sickle cell disease treatment market in 2024. The regions covered in sickle cell disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the sickle cell disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sickle cell disease treatment market consists of revenues earned by entities by providing services such as oxygen therapy, pulmonary hypertension management and pain management. The market value includes the value of related goods sold by the service provider or included within the service offering. The sickle cell disease treatment market also includes sales of hydroxyurea, L-glutamine and voxlelotor. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sickle Cell Disease Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on sickle cell disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for sickle cell disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The sickle cell disease treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Treatment Modality: Blood Transfusion; Pharmacotherapy; Bone Marrow Transplant
2) By Disease Type: Sickle Cell Anemia; Hemoglobin Sickle C Disease (HbSC); Other Disease Types
3) By Route Of Administration: Oral; Parenteral
4) By End-User: Hospitals; Specialty Clinics; Other End-Users
Subsegments:
1) By Blood Transfusion: Regular Blood Transfusion; Exchange Transfusion
2) By Pharmacotherapy: Hydroxyurea; L-Glutamine; Voxelotor; Crizanlizumab
3) By Bone Marrow Transplant: Allogeneic Transplant; Autologous Transplant
Companies Mentioned: Sun Pharmaceutical Industries Ltd.; Pfizer Inc.; Johnson & Johnson Private Limited; Merck & Co Inc.; Novartis AG; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca plc; Eli Lilly and Company; Gilead Sciences Inc.; Amgen Inc.; Baxter International Inc.; Teva Pharmaceutical Industries Ltd.; Vertex Pharmaceuticals Incorporated; Alnylam Pharmaceuticals Inc.; Ionis Pharmaceuticals Inc.; Silver Lake Research Corporation0.45; Global Blood Therapeutics Inc.; Acceleron Pharma Inc.; Sangamo Therapeutics Inc.; Medunik USA Inc.; Zydus Cadila Healthcare Ltd.; Graphite Bio Inc.; Addmedica; Emmaus Medical Inc.; Bluebird bio Inc.; CRISPR Therapeutics AG; GlycoMimetics Inc.; Arena Pharmaceuticals Inc.; Mast Therapeutics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r28980u

1. Executive Summary

2. Sickle Cell Disease Treatment Market Characteristics

3. Sickle Cell Disease Treatment Market Trends And Strategies

4. Sickle Cell Disease Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Sickle Cell Disease Treatment Growth Analysis And Strategic Analysis Framework

5.1. Global Sickle Cell Disease Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Sickle Cell Disease Treatment Market Growth Rate Analysis
5.4. Global Sickle Cell Disease Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Sickle Cell Disease Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Sickle Cell Disease Treatment Total Addressable Market (TAM)

6. Sickle Cell Disease Treatment Market Segmentation

6.1. Global Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Blood Transfusion
Pharmacotherapy
Bone Marrow Transplant
6.2. Global Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Sickle Cell Anemia
Hemoglobin Sickle C Disease (HbSC)
Other Disease Types
6.3. Global Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
6.4. Global Sickle Cell Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Other End-Users
6.5. Global Sickle Cell Disease Treatment Market, Sub-Segmentation Of Blood Transfusion, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Regular Blood Transfusion
Exchange Transfusion
6.6. Global Sickle Cell Disease Treatment Market, Sub-Segmentation Of Pharmacotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hydroxyurea
L-Glutamine
Voxelotor
Crizanlizumab
6.7. Global Sickle Cell Disease Treatment Market, Sub-Segmentation Of Bone Marrow Transplant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Allogeneic Transplant
Autologous Transplant

7. Sickle Cell Disease Treatment Market Regional And Country Analysis

7.1. Global Sickle Cell Disease Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Sickle Cell Disease Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Sickle Cell Disease Treatment Market

8.1. Asia-Pacific Sickle Cell Disease Treatment Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Sickle Cell Disease Treatment Market

9.1. China Sickle Cell Disease Treatment Market Overview
9.2. China Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Sickle Cell Disease Treatment Market

10.1. India Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Sickle Cell Disease Treatment Market

11.1. Japan Sickle Cell Disease Treatment Market Overview
11.2. Japan Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Sickle Cell Disease Treatment Market

12.1. Australia Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Sickle Cell Disease Treatment Market

13.1. Indonesia Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Sickle Cell Disease Treatment Market

14.1. South Korea Sickle Cell Disease Treatment Market Overview
14.2. South Korea Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Sickle Cell Disease Treatment Market

15.1. Western Europe Sickle Cell Disease Treatment Market Overview
15.2. Western Europe Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Sickle Cell Disease Treatment Market

16.1. UK Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Sickle Cell Disease Treatment Market

17.1. Germany Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Sickle Cell Disease Treatment Market

18.1. France Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Sickle Cell Disease Treatment Market

19.1. Italy Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Sickle Cell Disease Treatment Market

20.1. Spain Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Sickle Cell Disease Treatment Market

21.1. Eastern Europe Sickle Cell Disease Treatment Market Overview
21.2. Eastern Europe Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Sickle Cell Disease Treatment Market

22.1. Russia Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Sickle Cell Disease Treatment Market

23.1. North America Sickle Cell Disease Treatment Market Overview
23.2. North America Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Sickle Cell Disease Treatment Market

24.1. USA Sickle Cell Disease Treatment Market Overview
24.2. USA Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Sickle Cell Disease Treatment Market

25.1. Canada Sickle Cell Disease Treatment Market Overview
25.2. Canada Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Sickle Cell Disease Treatment Market

26.1. South America Sickle Cell Disease Treatment Market Overview
26.2. South America Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Sickle Cell Disease Treatment Market

27.1. Brazil Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Sickle Cell Disease Treatment Market

28.1. Middle East Sickle Cell Disease Treatment Market Overview
28.2. Middle East Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Sickle Cell Disease Treatment Market

29.1. Africa Sickle Cell Disease Treatment Market Overview
29.2. Africa Sickle Cell Disease Treatment Market, Segmentation By Treatment Modality, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Sickle Cell Disease Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Sickle Cell Disease Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Sickle Cell Disease Treatment Market Competitive Landscape And Company Profiles

30.1. Sickle Cell Disease Treatment Market Competitive Landscape
30.2. Sickle Cell Disease Treatment Market Company Profiles
- 30.2.1. Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Sickle Cell Disease Treatment Market Other Major And Innovative Companies

31.1. Sanofi S.A.
31.2. Bristol-Myers Squibb Company
31.3. AstraZeneca plc
31.4. Eli Lilly and Company
31.5. Gilead Sciences Inc.
31.6. Amgen Inc.
31.7. Baxter International Inc.
31.8. Teva Pharmaceutical Industries Ltd.
31.9. Vertex Pharmaceuticals Incorporated
31.10. Alnylam Pharmaceuticals Inc.
31.11. Ionis Pharmaceuticals Inc.
31.12. Silver Lake Research Corporation0.45
31.13. Global Blood Therapeutics Inc.
31.14. Acceleron Pharma Inc.
31.15. Sangamo Therapeutics Inc.

32. Global Sickle Cell Disease Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Sickle Cell Disease Treatment Market

34. Recent Developments In The Sickle Cell Disease Treatment Market

35. Sickle Cell Disease Treatment Market High Potential Countries, Segments and Strategies

35.1 Sickle Cell Disease Treatment Market In 2029 - Countries Offering Most New Opportunities
35.2 Sickle Cell Disease Treatment Market In 2029 - Segments Offering Most New Opportunities
35.3 Sickle Cell Disease Treatment Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer